IE
ABCL icon

Israel Englander’s AbCellera Biologics ABCL Stock Holding History

Israel Englander’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-297,200
Closed -$3.17M – 7004
2022
Q2 		$3.17M Buy
+297,200
New +$2.52M ﹤0.01% 3239

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Israel Englander's ABCL Position: Q2 2026 in Review

Israel Englander reduced its AbCellera Biologics (ABCL) stake by 60% in Q2 2026, selling an estimated $3.79M and leaving 518,571 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3195.

Israel Englander first reported a position in ABCL in Q4 2020 and has held it in 23 quarters since. The position peaked at $31.5M in Q2 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Israel Englander held 518,571 shares of AbCellera Biologics worth $4.07M as of Q2 2026.
  • Israel Englander sold 776,003 AbCellera Biologics shares in Q2 2026, an estimated $3.79M.
  • AbCellera Biologics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3195 holding.
  • Israel Englander first reported a position in AbCellera Biologics in Q4 2020 and has held it in 23 quarters since.
  • Israel Englander's AbCellera Biologics position peaked at $31.5M in Q2 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.